Data / Drug companies / Voyant Beauty, Inc.
Voyant Beauty, Inc.: 8 products in the FDA NDC directory, labeler code 61047
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Voyant Beauty, Inc. (labeler code 61047) lists 8 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 6 drugs for further processing, 2 over the counter drugs. Its main marketing category is drugs for further processing. The newest product started marketing on March 10, 2026.
The request: Watch Voyant Beauty, Inc. (FDA labeler code 61047): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61047
- Products in commercial distribution
- 8
- Packages
- 10
- Finished drugs by generic name
- 1
- Prescription products
- 0
- Over the counter products
- 2
- Flagged as original packager
- 2 of 2 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- February 20, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 6 | 75% |
| New drug applications (NDA) | 2 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 6 | 75% |
| Over the counter drugs | 2 | 25% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Terbinafine hydrochloride | 2 | 39 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Lotion | 6 | 75% |
| Cream | 2 | 25% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Allylamine Antifungal | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Avobenzone,homosalate, octisalate, octocrylene | 61047-157 | Lotion | Drugs for further processing | March 10, 2026 |
| Avobenzone,homosalate, octisalate, octocrylene | 61047-147 | Lotion | Drugs for further processing | March 4, 2025 |
| Titanium dioxide, zinc oxide lotion | 61047-142 | Lotion | Drugs for further processing | September 13, 2024 |
| Avobenzone, homosalate, octisalate, octocrylene lotion | 61047-141 | Lotion | Drugs for further processing | September 9, 2024 |
| Lamisil at terbinafine hydrochloride | 61047-139 | Cream | New drug applications (NDA) | August 21, 2024 |
| Avobenzone, homosalate, octisalate, octocrylene | 61047-134 | Lotion | Drugs for further processing | June 3, 2024 |
| Titanium dioxide, zinc oxide lotion | 61047-126 | Lotion | Drugs for further processing | October 6, 2023 |
| Lamisil AT Cream | 61047-120 | Cream | New drug applications (NDA) | February 20, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.